STAT‐3 contributes to pulmonary fibrosis through epithelial injury and fibroblast‐myofibroblast differentiation
Open accessThe DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Abstract
Lung fibrosis is the hallmark of the interstitial lung diseases. Alveolar epithelial cell (AEC) injury is akey step that contributes to a profibrotic microenvironment. Fibroblasts and myofibroblasts subsequently accumulate and deposit excessive extracellular matrix. In addition to TGF‐β, the IL‐6 family of cytokines, which signal through STAT‐3, may also contribute to lung fibrosis. In the current manuscript, the extent to which STAT‐3 inhibition decreases lung fibrosis is investigated. Phosphorylated STAT‐3 was elevated in lung biopsies from patients with idiopathic pulmonary fibrosis and bleomycin (BLM)‐induced fibrotic murine lungs. C‐188‐9, a small molecule STAT‐3 inhibitor, decreased pulmonary fibrosis in the intraperitoneal BLM model as assessed by arterial oxygen saturation (control, 84.4 ± 1.3%; C‐188‐9, 94.4 ± 0.8%), histology (Ashcroft score: untreated, 5.4 ± 0.25; C‐188‐9, 3.3 ± 0.14), and attenuated fibrotic markers such as diminished α‐smooth muscle actin, reduced collagen deposition. In addition, C‐188‐9 decreased the expression of epithelial injury markers, including hypoxia‐inducible factor‐1α (HIF‐1α) and plasminogen activator inhibitor‐1 (PAI‐1). In vitro studies show that inhibition of STAT‐3 decreased IL‐6‐ and TGF‐β‐induced expression of multiple genes, including HIF‐1α and PAI‐1, in AECs. Furthermore, C‐188‐9 decreased fibroblast‐to‐myofibroblast differentiation. Finally, TGF‐β stimulation of lung fibroblasts resulted in SMAD2/SMAD3‐dependent phosphorylation of STAT‐3. These findings demonstrate that STAT‐3 contributes to the development of lung fibrosis and suggest that STAT‐3 may be a therapeutic target in pulmonary fibrosis.—Pedroza, M., Le, T. T., Lewis, K., Karmouty‐Quintana, H., To, S., George, A. T., Blackburn, M. R., Tweardy, D. J., Agarwal, S. K. STAT‐3 contributes to pulmonary fibrosis through epithelial injury and fibroblast‐myofibroblast differentiation. FASEB J. 30, 129‐140 (2016). www.fasebj.org
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bleomycin induced pulmonary fibrosis occurs in a two-step process: 1) the immediate phase consists of an influx of macrophages and polymorphonuclear leukocytes, which release reactive oxygen species, then 2) extracellular matrix remodeling and collagen deposition [180,181].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [181]
In the citing paper
“Both TTI-101 and S3I-201 have been tested in several mouse models of fibrosis, including bleomycin-induced lung and skin fibrosis (scleroderma) and genetically-engineered models of scleroderma, as well as a model mouse of interstitial kidney fibrosis induced by unilateral ureteral obstruction, in which inhibition of STAT3 phosphorylation by these compounds blocks the development of organ fibrosis”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Pedroza et al., 2016
In the citing paper
“Importantly, in both bleomycin induced skin and lung fibrosis in mice, knockout or pharmacological inhibition of STAT3 ameliorates fibrosis (83) (81). Furthermore, in both models, STAT3 was shown to be downstream of TGFβ signaling, as inhibition of STAT3 prevented TGFβ-induced myofibroblasts formation (81, 83).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [83]
Citations
Cites
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201 · cited 1×
“Activation of STAT-3 regulates multiple biologic functions, including cell survival, migration, proliferation, and differentiation (51).”
BackgroundInterleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
Simple method of estimating severity of pulmonary fibrosis on a numerical scale.
Ashcroft, T., Simpson, J. M., & Timbrell, V (1988) · Journal of Clinical Pathology · doi:10.1136/jcp.41.4.467 · Cited by 1,680 · cited 1×
“H&Estained lung sections were used to determine the Ashcroft score using 20 microscope fields per section in a blinded manner (41, 42).”
MethodInterleukin-6 family of cytokines and gp130
Kishimoto, T., Akira, S., Narazaki, M., & Taga, T. (1995) · Blood · doi:10.1182/blood.v86.4.1243.bloodjournal8641243 · Cited by 1,272
Kim, K. K., Kugler, M. C., Wolters, P. J., Robillard, L., Galvez, M. G., Brumwell, A. N., Sheppard, D., & Chapman, H. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605669103 · Cited by 1,257 · cited 1×
“Current literature suggests that injury to type II AECs leads to the expression of injury markers, including HIF-1a, PAI-1, and HSP-70 (45–47, 58–60), and fibrotic markers, including Col1a1, a-SMA, TWIST, and SNAIL (4, 12, 14, 61).”
BackgroundMoeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007 · cited 1×
“The intraperitoneal model is associated with progressive subpleural pulmonary fibrosis, which resembles human pulmonary fibrosis to a greater extent than the intratracheal (40, 56, 57).”
BackgroundWillis, B. C., Liebler, J. M., Luby-Phelps, K., Nicholson, A. G., Crandall, E. D., du Bois, R. M., & Borok, Z. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62351-6 · Cited by 951
The epidemiology of interstitial lung diseases.
Coultas, D. B., Zumwalt, R. E., Black, W. C., & Sobonya, R. E. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.150.4.7921471 · Cited by 946
Standardized Quantification of Pulmonary Fibrosis in Histological Samples
Hübner, R.-H., Gitter, W., Eddine El Mokhtari, N., Mathiak, M., Both, M., Bolte, H., Freitag-Wolf, S., & Bewig, B. (2008) · BioTechniques · doi:10.2144/000112729 · Cited by 817
Cited by
Nieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314
“…in which inhibition of STAT3 phosphorylation by these compounds blocks the development of organ fibrosis by reducing expression levels of proteins that mediate fibrosis and impairing myofibroblast differentiation (Pang et al., 2010; Pedroza et al., 2016, 2017; Chakraborty et al., 2017).”
BackgroundSelf-citationRole of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms
Montero, P., Milara, J., Roger, I., & Cortijo, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126211 · Cited by 254
“Further, STAT3 regulates IL-6–mediated and TGF-β1–mediated myofibroblast differentiation in murine lung fibroblasts [30], and inhibition of STAT3 was found to reduce TGFβ1-induced FMT in fibroblasts, and ameliorate skin fibrosis in two mouse models of systemic sclerosis [82].”
BackgroundInfluentialCellular senescence: Molecular mechanisms and pathogenicity
Wei, W., & Ji, S. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26956 · Cited by 210
“Inhibition of STAT3 reduces the expression of IL‐6 and TGF‐β‐regulated gene expression, and decreases fibroblast‐ to‐myofibroblast differentiation (Pedroza et al., 2015).”
BackgroundKasembeli, M. M., Bharadwaj, U., Robinson, P., & Tweardy, D. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082299 · Cited by 199
“Additionally, myofibroblast differentiation was mitigated [63].”
BackgroundSelf-citationZhang, J., Wang, D., Wang, L., Wang, S., Roden, A. C., Zhao, H., Li, X., Prakash, Y. S., Matteson, E. L., Tschumperlin, D. J., et al. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00301.2018 · Cited by 194
“Recent studies have also implicated a role for JAK2 and STAT3-dependent signaling in lung fibrosis (2, 38, 44, 47, 49, 50) and ECM regulation (44, 67).”
BackgroundThe JAK2 pathway is activated in idiopathic pulmonary fibrosis
Milara, J., Hernandez, G., Ballester, B., Morell, A., Roger, I., Montero, P., Escrivá, J., Lloris, J. M., Molina-Molina, M., Morcillo, E., et al. (2018) · Respiratory Research · doi:10.1186/s12931-018-0728-9 · Cited by 188
“However, recent evidence indicates that in fibroblasts from IPF patients, TGF-β1 activates STAT3 via a SMAD2/3-dependent mechanism, independent of JAK2 [12].”
BackgroundResultEpstein Shochet, G., Brook, E., Bardenstein-Wald, B., & Shitrit, D. (2020) · Respiratory Research · doi:10.1186/s12931-020-1319-0 · Cited by 166
“and others [19, 30, 41] didn’t state which of the two phosphorylated STAT3s was tested.”
BackgroundVirus infection induced pulmonary fibrosis
Huang, W. J., & Tang, X. X. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03159-9 · Cited by 164
“IL-6 has been shown to promote pulmonary fibrosis through the STAT pathway [97] (Fig.”
BackgroundThe Role of IL-6 in Fibrotic Diseases: Molecular and Cellular Mechanisms
Li, Y., Zhao, J., Yin, Y., Li, K., Zhang, C., & Zheng, Y. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.75876 · Cited by 164
“In terms of cellular mechanisms, alveolar epithelial cell damage is a key stage in the pathogenesis of lung fibrosis, as it can lead to dysregulated activation and establish a profibrotic microenvironment [46, 47].”
BackgroundUnraveling SSc Pathophysiology; The Myofibroblast
van Caam, A., Vonk, M., van den Hoogen, F., van Lent, P., & van der Kraan, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02452 · Cited by 153
“Importantly, in both bleomycin induced skin and lung fibrosis in mice, knockout or pharmacological inhibition of STAT3 ameliorates fibrosis (83) (81).”
BackgroundPovedano, J. M., Martinez, P., Serrano, R., Tejera, Á., Gómez-López, G., Bobadilla, M., Flores, J. M., Bosch, F., & Blasco, M. A. (2018) · eLife · doi:10.7554/elife.31299 · Cited by 139
Zhang, Y., Lu, W., Zhang, X., Lü, J., Xu, S., Chen, S., Zhong, Z., Zhou, T., Wang, Q., Chen, J., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104307 · Cited by 129
Han, D., Gong, H., Wei, Y., Xu, Y., Zhou, X., Wang, Z., & Feng, F. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154680 · Cited by 134
Akamata, K., Wei, J., Bhattacharyya, M., Cheresh, P., Bonner, M. Y., Arbiser, J. L., Raparia, K., Gupta, M. P., Kamp, D. W., & Varga, J. (2016) · Oncotarget · doi:10.18632/oncotarget.12504 · Cited by 109
“Activation of Stat3, an important mediator of cytokine signaling linked to fibrosis, was also attenuated [40].”
BackgroundBijkerk, R., de Bruin, R. G., Solingen, C. V., van Gils, J. M., Duijs, J. M. G. J., van der Veer, E. P., Rabelink, T. J., Humphreys, B. D., & van Zonneveld, A. J. (2016) · Kidney International · doi:10.1016/j.kint.2016.01.029 · Cited by 114
Contribution of STAT3 to the pathogenesis of COVID-19
Jafarzadeh, A., Nemati, M., & Jafarzadeh, S. (2021) · Microbial Pathogenesis · doi:10.1016/j.micpath.2021.104836 · Cited by 116
ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer
Schumacher, N., & Rose‐John, S. (2019) · Cancers · doi:10.3390/cancers11111736 · Cited by 113
“The development of pulmonary fibrosis in mice and differentiation of lung fibroblasts to collagen-producing myofibroblasts involves STAT3 activation by TGFß or IL-6 trans-signaling [130].”
BackgroundHu, L., Yu, Y., Huang, H., Fan, H., Hu, L., Yin, C., Li, K., Fulton, D. J. R., & Chen, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00696 · Cited by 100
“A growing body of studies indicates that IL-6 takes part in occurrence and development of fibrosis diseases (19, 20, 52, 53).”
BackgroundCombined inhibition of TGFβ and PDGF signaling attenuates radiation-induced pulmonary fibrosis
Dadrich, M., Nicolay, N. H., Flechsig, P., Bickelhaupt, S., Hoeltgen, L., Roeder, F., Hauser, K., Tietz, A., Jenne, J., Perez, R. L., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1123366 · Cited by 106
“STAT3 has been reported to have antifibrotic effects but the definitive role of STAT3 and the IL6-STAT3 pathway in lung fibrosis is unclear and the published results are conflicting.(53,54)”
ResultThe JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib
Wang, W., Bhattacharyya, S., Marangoni, R. G., Carns, M. A., Dennis‐Aren, K., Yeldandi, A. V., Wei, J., & Varga, J. (2019) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198319865367 · Cited by 107
Wang, M., Gauthier, A. G., Daley, L.-A., Dial, K., Wu, J., Woo, J., Lin, M., Ashby, C. R., & Mantell, L. L. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7818 · Cited by 101
“As a mediator of vascular remodeling, TGF-b1 can induce phosphorylation of SMAD2 and SMAD3, which can phosphorylate the transcription factor signal transducer and activator of transcription 3 (STAT-3) (251, 316).”
InfluentialThe role of hypoxia-inducible factors in cardiovascular diseases
Yu, B., Wang, X., Song, Y., Xie, G., Jiao, S., Shi, L., Cao, X., Han, X., & Qu, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108186 · Cited by 93
Milara, J., Ballester, B., Morell, A., Ortiz, J. L., Escrivá, J., Fernández, E., Pérez‐Vizcaíno, F., Cogolludo, A. L., Pastor, E., Artigues, E., et al. (2018) · Thorax · doi:10.1136/thoraxjnl-2017-210728 · Cited by 88
Aminoacyl-tRNA synthetases and amino acid signaling
Yu, Y. C., Han, J. M., & Kim, S. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118889 · Cited by 91
Duke, K. S., & Bonner, J. C. (2017) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1498 · Cited by 88
Emerging delivery approaches for targeted pulmonary fibrosis treatment
Diwan, R., Bhatt, H., Beaven, E., & Nurunnabi, M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115147 · Cited by 89
Pinto, E. B., Sawazaki‐Calone, Í., Macedo, C. C. S., Carnielli, C. M., de Oliveira, C. E., Rodrigues, P. C., Rangel, A. L. C. A., dos Santos, J. N., Risteli, J., Graner, E., et al. (2016) · Tumor Biology · doi:10.1007/s13277-015-4629-y · Cited by 78
“Interestingly, C-188-9, a STAT-3 inhibitor, decreased pulmonary fibrosis and resulted in inhibition of fibroblast-to-myofibroblast differentiation and TGF-β-induced expression of multiple genes including SERPINE1 [42].”
BackgroundT cell abnormalities in systemic sclerosis
Jin, W., Zheng, Y., & Zhu, P. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103185 · Cited by 90
Lipid nanoparticle-mediated mRNA delivery in lung fibrosis
Massaro, M., Wu, S., Baudo, G., Liu, H., Collum, S. D., Lee, H., Stigliano, C., Segura-Ibarra, V., Karmouty‐Quintana, H., & Blanco, E. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106370 · Cited by 82
“These mediators contribute to fibroblast differentiation into myofibroblasts, the latter adopting an apoptosis-resistant phenotype that continuously secretes ECM components (Pedroza et al., 2016).”
BackgroundSelf-citationYu, B., Liu, Z., Fu, Y., Wang, Y., Zhang, L., Cai, Z., Yu, F., Wang, X., Zhou, J., & Kong, W. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309859 · Cited by 77
Role of STAT3 in skin fibrosis and transforming growth factor beta signalling
Pedroza, M., To, S., Assassi, S., Wu, M., Tweardy, D. J., & Agarwal, S. K. (2017) · Rheumatology · doi:10.1093/rheumatology/kex347 · Cited by 82
Self-citationFibroblast‐specific IL11 signaling drives chronic inflammation in murine fibrotic lung disease
Ng, B., Dong, J., Viswanathan, S., Widjaja, A. A., Paleja, B. S., Adami, E., Ko, N. S. J., Wang, M., Lim, S., Tan, J., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202001045rr · Cited by 74
Zhou, B., Liu, H., Xu, F., & Jia, X. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01557-2 · Cited by 84
“In addition, upregulation of the IL-6 pathway by JAK/STAT signalling has been shown to drive senescent gene transcription both in IPF epithelial cells and fibroblasts [73, 74].”
BackgroundTargeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option
Korfei, M., Mahavadi, P., & Guenther, A. (2022) · Cells · doi:10.3390/cells11101626 · Cited by 72
“It could also be demonstrated that C-188-9, a small molecule STAT3 inhibitor that targets the Tyr705 peptide binding pocket, decreased FMD induced by TGF-β in cultured lung fibroblasts as well as significantly reduced experimental pulmonary fibrosis in mice [69].”
BackgroundPapaioannou, I., Xu, S., Denton, C. P., Abraham, D. J., & Ponticos, M. (2018) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-06-0342 · Cited by 64
“Pedroza et al. (2016) appear at first glance to arrive at a different conclusion.”
BackgroundHeiß, E. H., Schachner, D., Donati, M., Grojer, C. S., & Dirsch, V. M. (2016) · Vascular Pharmacology · doi:10.1016/j.vph.2016.05.002 · Cited by 63
“However, taking into account that HIF-1α is also a STAT3 target gene [35,44] and I3MO acts as an inhibitor of Heiss et al.”
BackgroundHMGB1 induces lung fibroblast to myofibroblast differentiation through NF-κB-mediated TGF-β1 release
Wang, Q., Wang, J., Wang, J., Hong, S., Han, F., Chen, J., & Chen, G. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6364 · Cited by 68
“Signal transducer and activator of transcription‑3 (STAT‑3) has been reported to contribute to lung fibrosis through epithelial injury and fibroblast to myofibroblast differentiation (39).”
Etiology and Pathogenesis of Rheumatoid Arthritis-Interstitial Lung Disease
Kim, Y., Yang, H.-I., & Kim, K. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914509 · Cited by 75
“In murine lung fibroblasts, signal transducers and activators of transcription (STAT)3 contributed to the lung fibrosis by stimulating interleukin (IL)-6- and TGF-β 1-mediated myofibroblast differentiation [128].”
BackgroundSontake, V., Kasam, R. K., Sinner, D. I., Korfhagen, T. R., Reddy, G. B., White, E. S., Jegga, A. G., & Madala, S. K. (2018) · JCI Insight · doi:10.1172/jci.insight.121252 · Cited by 62
IL-6 family cytokines in respiratory health and disease
Dawson, R., Jenkins, B. J., & Saad, M. I. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155520 · Cited by 74
Korfei, M., Stelmaszek, D., MacKenzie, B., Skwarna, S., Chillappagari, S., Bach, A., Ruppert, C., Saito, S., Mahavadi, P., Klepetko, W., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207915 · Cited by 64
“Levels of p-STAT3 have been shown to be elevated in the bleomycin mouse model and in patients with IPF [19,20,67], and were recently observed to be overexpressed in the nucleus of myofibroblasts, alveolar macrophages and of AECIIs adjacent to fibroblast foci, while being absent in non-fibrotic healthy control lungs [2…”
BackgroundInfluentialMacrophage polarization in tissue fibrosis
Yang, H., Cheng, H., Dai, R., Shang, L., Zhang, X., & Wen, H. (2023) · PeerJ · doi:10.7717/peerj.16092 · Cited by 69
“Many studies have confirmed that JAK/STAT3 signaling plays an important role in the pathogenesis of fibrosis, and the up-regulation of STAT3 expression has been detected in fibrotic tissues ( Ogata et al., 2006 ; Pechkovsky et al., 2012 ; Pedroza et al., 2016 ).”
BackgroundNintedanib induces senolytic effect via STAT3 inhibition
Cho, H.-J., Hwang, J.-A., Yang, E. J., Kim, E.-C., Kim, J., Kim, S. Y., Kim, Y. Z., Park, S. C., & Lee, Y. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05207-8 · Cited by 65
Oh, R. S., Haak, A. J., Smith, K. M. J., Ligresti, G., Choi, K. M., Xie, T., Wang, S., Walters, P. R., Thompson, M. A., Freeman, M. R., et al. (2018) · Journal of Cell Science · doi:10.1242/jcs.209932 · Cited by 56
“Increased STAT3 activation has previously been documented in samples taken from fibrotic human lung tissue (Milara et al., 2018; O’Donoghue et al., Jo u rn al o f Ce ll Sc ie n ce 2012; Pedroza et al., 2015).”
BackgroundResultInfluentialLiu, B., Li, R., Zhang, J., Meng, C., Zhang, J., Song, X., & Lv, C. (2018) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.311 · Cited by 55
Bisserier, M., Milara, J., Abdeldjebbar, Y., Gubara, S. M., Jones, C. R., Bueno‐Betí, C., Chepurko, E., Kohlbrenner, E., Katz, M. G., Tarzami, S. T., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.027 · Cited by 52
Xing, D., Xia, G., Tang, X.-D., Zhuang, Z., Shan, J., Fang, X., Qiu, L., Zha, X., & Chen, X. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401619 · Cited by 51
Guo, X., Yan, F., Li, J., Zhang, C., & Bu, P. (2017) · PubMed Central · Cited by 55
Dong, H., Luo, L., Zou, M., Huang, C., Wan, X., Hu, Y., Le, Y., Zhao, H., Li, W., Zou, F., et al. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00489.2016 · Cited by 42
LncRNA GAS5 attenuates fibroblast activation through inhibiting Smad3 signaling
Tang, R., Wang, Y.-C., Mei, X., Shi, N., Sun, C., Ran, R., Zhang, G., Li, W., Staveley-O’Carroll, K. F., Li, G., et al. (2020) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00059.2020 · Cited by 45
Ruan, H., Luan, J., Gao, S., Li, S., Jiang, Q., Liu, R., Liang, Q. L., Zhang, R., Zhang, F., Li, X., et al. (2021) · Molecules · doi:10.3390/molecules26154491 · Cited by 44
Zhu, Y., Feng, Z., Zhao, J., & Xiao, Y. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9327 · Cited by 40
Baicalein represses TGF-β1-induced fibroblast differentiation through the inhibition of miR-21
Cui, X., Sun, X., Lu, F., & Jiang, X. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.09.007 · Cited by 42
Marden, G., Wan, Q., Wilks, J., Nevin, K., Feeney, M., Wisniacki, N., Trojanowski, M. A., Bujor, A. M., Stawski, L., & Trojanowska, M. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-020-02266-0 · Cited by 40
“tivated (phosphorylated) form of STAT3 are elevated in the skin and lung of SSc patients, suggesting that it is involved in SSc pathogenesis [31, 32].”
BackgroundCao, J., Li, L., Xiong, L., Wang, C., Chen, Y., & Zhang, X. (2022) · Phytomedicine Plus · doi:10.1016/j.phyplu.2022.100252 · Cited by 38
“Studies have shown that by targeting the upstream components of the JAK/STAT3 signaling pathway, the expression of fibrotic genes induced by TGF-β can be reduced (Pedroza et al., 2016; Milara et al., 2018; Sallam et al., 2018).”
BackgroundTRPM7 modulates macrophage polarization by STAT1/STAT6 pathways in RAW264.7 cells
Li, L., Wei, C., Cai, S., & Fang, L. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.062 · Cited by 36
Ma, K., Li, C., Xu, J., Ren, F., Xu, X. Y., Liu, C., Niu, B., & Li, F. (2020) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2020.111327 · Cited by 33
Romano, E., Rosa, I., Fioretto, B. S., Matucci‐Cerinic, M., & Manetti, M. (2021) · Life · doi:10.3390/life11070610 · Cited by 40
Dong, Z., Zhao, X., Tai, W., Lei, W., Wang, Y., Li, Z., & Zhang, T. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.01.004 · Cited by 34
Xu, Q., Liu, Y., Pan, H., Xu, T., Li, Y., Yuan, J., Li, P., Yao, W., Yan, W., & Ni, C. (2019) · Toxicology · doi:10.1016/j.tox.2019.01.007 · Cited by 32
New insights into the pathogenesis of Peyronie's disease: A narrative review
Krakhotkin, D. V., Chernylovskyi, V. A., Mottrie, A., Greco, F., & Bugaev, R. A. (2020) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2020.06.001 · Cited by 32
“The pharmacological inhibition of JAK and STAT proteins suppresses the production of collagen IV, fibronectin, and other components of fibrotic tissue by decreasing the expression of pro-fibrogenic factors.(140) Tao et al(141) found increased proliferation and differentiation in human hypertrophic scar fibroblasts tre…”
BackgroundFibroblasts and their responses to chronic injury in pulmonary fibrosis
Wu, B., Tang, L. F., & Kapoor, M. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.12.003 · Cited by 37
Liu, T.-T., Sun, H.-F., Tang, M.-Z., Shen, H.-R., Shen, Z., Han, Y., Zhan, Y., & Jiang, J. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05399-x · Cited by 35
Deleterious Role of Th9 Cells in Pulmonary Fibrosis
Deng, K., Yang, X. S., Luo, Q., She, Y. X., Yu, Q. Y., & Tang, X. X. (2021) · Cells · doi:10.3390/cells10113209 · Cited by 36
“Activation of STAT3 participates in fibrosis pathways, leading to lung fibrosis by promoting epithelial damage and fibroblast activation [51,52].”
Lin, C., Shih, C.-H., Lin, Y.-C., Yang, Y.-L., & Chen, B.-C. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0421-9 · Cited by 29
“One of the key processes in pulmonary fibrosis is the activation of fibroblasts into myofibroblasts [3], a process that seems to be dependent on activation of the activator protein (AP)-1 and SMAD3 pathway [4, 5].”
Hoffman, K. A., Reynolds, C. L., Bottazzi, M. E., Hotez, P. J., & Jones, K. M. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013365 · Cited by 28
Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease
Huo, R., Guo, Q., Hu, J., Li, N., Gao, R., Mi, L., Zhang, Z., Liu, H., Guo, Z., Zhao, H., et al. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s353494 · Cited by 30
“The JAK/STAT pathway plays a significant role in the pathogenesis of ILD.”
BackgroundInfluentialInvolvement of NF-κBIZ and related cytokines in age-associated renal fibrosis
Chung, K. W., Jeong, H. O., Lee, B., Park, D., Kim, D. H., Choi, Y. J., Lee, E. K., Kim, K. M., Park, J. W., Yu, B. P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14614 · Cited by 30
Karataş, A., Öz, B., Celik, C., Akar, Z. A., Akkoç, R. F., Etem, E. Ö., Dağlı, A. F., & Koca, S. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-06581-1 · Cited by 35
Cadherin-11 contributes to liver fibrosis induced by carbon tetrachloride
Pedroza, M., To, S., Smith, J., & Agarwal, S. K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218971 · Cited by 31
Self-citationLi, C., Sun, X., Li, A., Mo, M., & Zhao, Z. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106110 · Cited by 26
Therapeutic Targeting of IL-11 for Chronic Lung Disease
Kortekaas, R. K., Burgess, J. K., van Orsoy, R., Lamb, D. J., Webster, M. J., & Gosens, R. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.01.007 · Cited by 26
Salminen, A. (2023) · Biogerontology · doi:10.1007/s10522-023-10072-9 · Cited by 31
Wang, X., Wan, W., Lü, J., Zhang, Y., Quan, G., Pan, X., Wu, Z., & Liu, P. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.02.012 · Cited by 30
Saber, S., Nasr, M., Kaddah, M. M. Y., Mostafa‐Hedeab, G., Cavalu, S. D., Mourad, A. A. E., Gaafar, A. G. A., Zaghlool, S. S., Saleh, S., Hafez, M. M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112731 · Cited by 27
Zhang, Y., Qin, X., Yang, Y., Li, J., Li, X., Zou, X., Huang, Z., & Huang, S. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154809 · Cited by 25
Keum, H., Kim, J., Yoo, D., Kim, T. W., Seo, C., Kim, D., & Jon, S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.022 · Cited by 28
Ji, H.-M., Dong, H., Lan, Y., Bi, Y., Gu, X., Han, Y., Yang, C., Cheng, M.-H., & Gao, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1089812 · Cited by 25
“IPF is a progressive interstitial lung disease characterized by fibroblasts activation and excessive ECM deposition.”
BackgroundInfluentialGenetic Deletion of Socs3 in Smooth Muscle Cells Ameliorates Aortic Dissection in Mice
Hirakata, S., Aoki, H., Ohno‐Urabe, S., Nishihara, M., Furusho, A., Nishida, N., Ito, S., Hayashi, M., Yasukawa, H., Imaizumi, T., et al. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.10.010 · Cited by 24
“Moreover, Stat3 activation is reportedly involved in fibrosis in renal (34), atrial (35), and pulmonary tissues (36).”
BackgroundSehgal, M., Jakhete, S. M., Manekar, A. G., & Sasikumar, S. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09773 · Cited by 24
“activate genes involved in increased myofibroblast generation, as well as in ECM and CTGF production [27, 28, 29, 30, 31, 32, 33, 34, 35, 36].”
Tieyuan, Z., Zhang, Y., Xinghua, Z., Huimin, W., & Huagang, L. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109107 · Cited by 26
Song, D., Kim, D., Jung, J. W., Nam, S. H., Kim, J. E., Kim, H., Kim, J. H., Pan, C., Kim, S., & Lee, S. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01337 · Cited by 26
“STAT3 is activated in the lungs of patients with IPF (Pechkovsky et al., 2012; Prele et al., 2012; Pedroza et al., 2016).”
BackgroundFiorentini, E., Bonomi, F., Peretti, S., Orlandi, M., Lepri, G., Matucci‐Cerinic, M., Bellando-Randone, S., & Guiducci, S. (2022) · Life · doi:10.3390/life12122101 · Cited by 29
“This amplified secretion of IL-6 can also induce STAT3-mediated fibroblast-to-mesenchymal transition (FMT) [31], resulting in de-differentiation of fibroblasts into myofibroblasts with a mesenchymal phenotype, contributing to the development of ILD [32].”
BackgroundThe Role of Pro-fibrotic Myofibroblasts in Systemic Sclerosis: From Origin to Therapeutic Targeting
Romano, E., Rosa, I., Fioretto, B. S., Matucci‐Cerinic, M., & Manetti, M. (2021) · Current Molecular Medicine · doi:10.2174/0929867328666210325102749 · Cited by 26
Advances in idiopathic pulmonary fibrosis diagnosis and treatment
Liu, H., Shen, J., & He, C. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.02.001 · Cited by 23
Metabolomics Data Preprocessing: From Raw Data to Features for Statistical Analysis
Karaman, İ., Pinto, R. C., & Graça, G. (2018) · Comprehensive analytical chemistry · doi:10.1016/bs.coac.2018.08.003 · Cited by 24
Wang, F., Wang, S., Zhang, C., Tian, X., Zhou, Y., Xuan, W., Matteson, E. L., Luo, F., Tschumperlin, D. J., & Vassallo, R. (2022) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00428.2021 · Cited by 24
Zhao, X., Sun, D., Zhang, A., Huang, H., Li, Y., & Xu, D. (2023) · Scientific Reports · doi:10.1038/s41598-022-25471-0 · Cited by 30
Novel role of NPY in neuroimmune interaction and lung growth after intrauterine growth restriction
Thangaratnarajah, C., Dinger, K., Vohlen, C., Klaudt, C., Nawabi, J., Garcia, E. L., Kwapiszewska, G., Dobner, J., Nüsken, K., Koningsbruggen-Rietschel, S. V., et al. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00432.2016 · Cited by 22
“Moreover, IL-6/STAT3 signaling has been reported to contribute to fibroblast-myofibroblast differentiation (42).”
BackgroundLiang, Y., Qu, L., Liu, Z., Liang, L., Wang, Y., Quan, S., Wang, Y., & Tang, L. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07588-7 · Cited by 22
“A number of studies have confirmed that activation of the STAT3 pathway is associated with the development and progression of fibrosis in a variety of diseases [25].”
BackgroundZhu, Y., Yao, J., Duan, Y., Xu, H., Cheng, Q., Gao, X., Li, S., Fang, Y., Liu, H., & Yuan, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041189 · Cited by 21
“We were unable to find any reports linking either PTPN2 to silicosis, and it has been reported that IL-6 family of cytokines, which signal through STAT-3, may contribute to lung fibrosis [14].”
BackgroundYao, Y., Ritzmann, F., Miethe, S., Kattler‐Lackes, K., Colakoglu, B., Herr, C., Kamyschnikow, A., Brand, M., Garn, H., Yildiz, D., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00990-w · Cited by 21
Regulator of Cell Cycle Protein (RGCC/RGC-32) Protects Against Pulmonary Fibrosis
Luzina, I. G., Rus, V., Lockatell, V., Courneya, J.-P., Hampton, B., Fishelevich, R., Misharin, A. V., Todd, N. W., Badea, T. C., Rus, H., et al. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0022oc · Cited by 19
Nitrogen dioxide increases the risk of disease progression in idiopathic pulmonary fibrosis
Yoon, H., Kim, S., Kim, O., & Song, J. W. (2022) · Respirology · doi:10.1111/resp.14373 · Cited by 27
Ding, L., Yang, Y., Wang, Z., Su, H., Li, Y., Ma, J., Bao, T., Qi, H., Song, S., Li, J., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154707 · Cited by 19
Inositol possesses antifibrotic activity and mitigates pulmonary fibrosis
Li, J.-M., Chang, W., Li, L., Yang, D. C. H., Hsu, S., Kenyon, N. J., & Chen, C. (2023) · Respiratory Research · doi:10.1186/s12931-023-02421-6 · Cited by 23
Hoffman, K. A., Villar, M. J., Poveda, C., Bottazzi, M. E., Hotez, P. J., Tweardy, D. J., & Jones, K. M. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.708325 · Cited by 21
“We propose the pathway illustrated in Figure 9 as the mechanism of pro-fibrotic communication that is the result of our findings combined with those of previous research, as summarized below (Negoro et al., 2000; Stahl et al., 2013; Stahl et al., 2014; Pedroza et al., 2016; Tang et al., 2017; Cevey et al., 2019).”
BackgroundResultInfluentialSelf-citationGracillin relieves pulmonary fibrosis by suppressing the STAT3 axis
Xie, M., Yang, L., Cheng, J., Qu, H., Gu, Y.-T., Ding, C., Xu, X., Zhao, C., Huang, X., & Wang, L. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116704 · Cited by 20
Influenza, SARS-CoV-2, and Their Impact on Chronic Lung Diseases and Fibrosis
Soni, S., Antonescu, L., Ro, K., Horowitz, J. C., Mebratu, Y. A., & Nho, R. S. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.06.004 · Cited by 20
Metadata
- Authors
- Pedroza, M., Le, T. T., Lewis, K., Karmouty‐Quintana, H., To, S., George, A. T., Blackburn, M. R., Tweardy, D. J., & Agarwal, S. K.
- Affiliations
- Baylor College of Medicine (US)
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Agarwal, Sandeep K.
- ORCID
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2015-08-31
- Volume
- 30
- Issue
- 1
- Pages
- 129-140
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- PMC
- PMC4684532
- OpenAlex
- W1853941740
- Cited by
- 193
- References
- 68
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 24 · 2023: 25 · 2022: 27 · 2021: 20 · 2020: 15 · 2019: 14 · 2018: 17 · 2017: 10 · 2016: 7 · 2015: 1
- FWCI
- 9.24
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The FASEB Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- National Institutes of Health (R01AR062056, K08AR054404, 2T32AI053831‐11A1)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- STAT3, pulmonary fibrosis, idiopathic pulmonary fibrosis, alveolar epithelial cell injury, myofibroblast differentiation, bleomycin-induced lung fibrosis, IL-6 signaling, TGF-beta signaling, HIF-1α, plasminogen activator inhibitor-1, extracellular matrix deposition, therapeutic target
- MeSH terms
- Animals, Bleomycin, Cell Differentiation, Disease Models, Animal, Epithelial Cells, Lung, Male, Mice, Inbred C57BL, STAT3 Transcription Factor, Idiopathic Pulmonary Fibrosis, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.